These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Effects of bromocriptine and haloperidol on prepulse inhibition: comparison of the acoustic startle eyeblink response and the N1/P2 auditory-evoked response in man. Abduljawad KA; Langley RW; Bradshaw CM; Szabadi E J Psychopharmacol; 1999; 13(1):3-9. PubMed ID: 10221354 [TBL] [Abstract][Full Text] [Related]
24. Direct evidence that acutely enhancing serotonin with the selective serotonin reuptake inhibitor citalopram modulates the loudness dependence of the auditory evoked potential (LDAEP) marker of central serotonin function. Nathan PJ; Segrave R; Phan KL; O'Neill B; Croft RJ Hum Psychopharmacol; 2006 Jan; 21(1):47-52. PubMed ID: 16317803 [TBL] [Abstract][Full Text] [Related]
25. D1 dopamine agonist effects assessed in vivo with [14C]-2-deoxyglucose autoradiography. Trugman JM; Arnold WS; Touchet N; Wooten GF J Pharmacol Exp Ther; 1989 Sep; 250(3):1156-60. PubMed ID: 2674418 [TBL] [Abstract][Full Text] [Related]
27. Dopamine agonist activities of pergolide, its metabolites, and bromocriptine as measured by prolactin inhibition, compulsive turning, and stereotypic behavior. Clemens JA; Okimura T; Smalstig EB Arzneimittelforschung; 1993 Mar; 43(3):281-6. PubMed ID: 8489554 [TBL] [Abstract][Full Text] [Related]
28. Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells. Coldwell MC; Boyfield I; Brown T; Hagan JJ; Middlemiss DN Br J Pharmacol; 1999 Aug; 127(7):1696-702. PubMed ID: 10455328 [TBL] [Abstract][Full Text] [Related]
29. Dopamine receptor affinities in vitro and neurochemical effects in vivo of pergolide and its metabolites. Wong DT; Threlkeld PG; Bymaster FP Arzneimittelforschung; 1993 Apr; 43(4):409-12. PubMed ID: 7684223 [TBL] [Abstract][Full Text] [Related]
30. Activation of D1 and D2 dopamine receptors increases the activity of the somatostatin receptor-effector system in the rat frontoparietal cortex. Izquierdo-Claros RM; del Boyano-Adánez M; Arilla-Ferreiro E J Neurosci Res; 2000 Oct; 62(1):91-8. PubMed ID: 11002291 [TBL] [Abstract][Full Text] [Related]
31. Effects of D3/D2 dopamine receptor agonists and antagonists on prepulse inhibition of acoustic startle in the rat. Caine SB; Geyer MA; Swerdlow NR Neuropsychopharmacology; 1995 Apr; 12(2):139-45. PubMed ID: 7779242 [TBL] [Abstract][Full Text] [Related]
32. Effect of repeated treatment with milnacipran on the central dopaminergic system. Rogóz Z; Margas W; Dlaboga D; Góralska M; Dziedzicka-Wasylewska M; Maj J Pol J Pharmacol; 2000; 52(2):83-92. PubMed ID: 10949109 [TBL] [Abstract][Full Text] [Related]
33. Dopaminergic Modulation of Lateral Amygdala Neuronal Activity: Differential D1 and D2 Receptor Effects on Thalamic and Cortical Afferent Inputs. Chang CH; Grace AA Int J Neuropsychopharmacol; 2015 Feb; 18(8):. PubMed ID: 25716776 [TBL] [Abstract][Full Text] [Related]
34. Dopamine D1 rather than D2 receptor agonists disrupt prepulse inhibition of startle in mice. Ralph-Williams RJ; Lehmann-Masten V; Geyer MA Neuropsychopharmacology; 2003 Jan; 28(1):108-18. PubMed ID: 12496946 [TBL] [Abstract][Full Text] [Related]
35. Increasing dopaminergic activity: effects of L-dopa and bromocriptine on human sensory gating. Oranje B; Gispen-de Wied CC; Westenberg HG; Kemner C; Verbaten MN; Kahn RS J Psychopharmacol; 2004 Sep; 18(3):388-94. PubMed ID: 15358983 [TBL] [Abstract][Full Text] [Related]
36. Heterodimerization of dopamine receptors: new insights into functional and therapeutic significance. Maggio R; Aloisi G; Silvano E; Rossi M; Millan MJ Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S2-7. PubMed ID: 20123551 [TBL] [Abstract][Full Text] [Related]
37. Cerebrospinal fluid-orexin levels and sleep attacks in four patients with Parkinson's disease. Asai H; Hirano M; Furiya Y; Udaka F; Morikawa M; Kanbayashi T; Shimizu T; Ueno S Clin Neurol Neurosurg; 2009 May; 111(4):341-4. PubMed ID: 19097685 [TBL] [Abstract][Full Text] [Related]
38. Antiparkinson therapeutic potencies correlate with their affinities at dopamine D2(High) receptors. Seeman P Synapse; 2007 Dec; 61(12):1013-8. PubMed ID: 17853435 [TBL] [Abstract][Full Text] [Related]
39. Morphine alters the locomotor responses to a D2/D3 dopamine receptor agonist differentially in adolescent and adult mice. Hofford RS; Wellman PJ; Eitan S J Psychopharmacol; 2012 Oct; 26(10):1355-65. PubMed ID: 22522973 [TBL] [Abstract][Full Text] [Related]